Implantable cardioverter-defibrillator therapy in contemporary heart failure patients: an analysis from the EMPEROR-reduced trial
Background - The benefit of an implantable cardioverter-defibrillator (ICD) in patients with heart failure with reduced ejection fraction on foundational therapy that includes a sodium-glucose cotransporter 2 inhibitor is unknown. - Objectives - This study aims to evaluate the impact of an ICD among...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Article (Journal) |
| Lenguaje: | inglés |
| Publicado: |
August 2026
|
| In: |
JACC Heart failure
Year: 2026, Volumen: 14, Número: 8, Pages: 1-10 |
| ISSN: | 2213-1787 |
| DOI: | 10.1016/j.jchf.2026.103166 |
| Acceso en línea: | Verlag, kostenfrei, Volltext: https://doi.org/10.1016/j.jchf.2026.103166 Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S2213177926002660 
|
| Notas de Autor: | Mehmet K. Aktas¸, MD, MBA, Khawaja M. Talha, MD, Ilan Goldenberg, MD, Wojciech Zareba, MD, PHD, Michael Böhm, MD, Amr Abdin, MD, Martina Brueckmann, MD, Cordula Zeller, DIPL-MATH, Liliana Zaremba-Pechmann, PHD, Stuart Pocock, PHD, Faiez Zannad, MD, PHD, Stefan D. Anker, MD, PHD, Gerasimos Filippatos, MD, Javed Butler, MD, MPH, MBA, João Pedro Ferreira, MD, PHD, Milton Packer, MD |
MARC
| LEADER | 00000naa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1982176334 | ||
| 003 | DE-627 | ||
| 005 | 20260820085457.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 260820s2026 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jchf.2026.103166 |2 doi | |
| 035 | |a (DE-627)1982176334 | ||
| 035 | |a (DE-599)KXP1982176334 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Aktaş, Mehmet K. |e VerfasserIn |0 (DE-588)1416909044 |0 (DE-627)1982176768 |4 aut | |
| 245 | 1 | 0 | |a Implantable cardioverter-defibrillator therapy in contemporary heart failure patients |b an analysis from the EMPEROR-reduced trial |c Mehmet K. Aktas¸, MD, MBA, Khawaja M. Talha, MD, Ilan Goldenberg, MD, Wojciech Zareba, MD, PHD, Michael Böhm, MD, Amr Abdin, MD, Martina Brueckmann, MD, Cordula Zeller, DIPL-MATH, Liliana Zaremba-Pechmann, PHD, Stuart Pocock, PHD, Faiez Zannad, MD, PHD, Stefan D. Anker, MD, PHD, Gerasimos Filippatos, MD, Javed Butler, MD, MPH, MBA, João Pedro Ferreira, MD, PHD, Milton Packer, MD |
| 264 | 1 | |c August 2026 | |
| 300 | |b Diagramme | ||
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online verfügbar: 2. Juli 2026, Artikelversion: 3. August 2026 | ||
| 500 | |a Gesehen am 20.08.2026 | ||
| 520 | |a Background - The benefit of an implantable cardioverter-defibrillator (ICD) in patients with heart failure with reduced ejection fraction on foundational therapy that includes a sodium-glucose cotransporter 2 inhibitor is unknown. - Objectives - This study aims to evaluate the impact of an ICD among participants enrolled in EMPEROR-Reduced (Empagliflozin Outcome Trial in Patients with Chronic Heart Failure and a Reduced Ejection Fraction). - Methods - Propensity score matching was used to compare outcomes in patients with and without an ICD in the placebo and empagliflozin arms of the EMPEROR-Reduced trial. Time-to-event curves and Cox regression analysis were used to evaluate the risk of the primary endpoint of sudden cardiac death (SCD). - Results - A total of 1,674 patients were included in the analysis of whom 837 (429 on placebo and 408 on empagliflozin) with an ICD at baseline were matched to 837 (424 on placebo and 413 on empagliflozin) without an ICD. Background therapy included an angiotensin-converting enzyme inhibitor/angiotensin receptor blocker/angiotensin receptor blocker-neprilysin inhibitor (≥88%); beta-blockers (≥94%), and mineralocorticoid receptor antagonists (≥65%). Cox regression analysis showed ICD vs non-ICD treatment was associated with a lower risk of SCD in both the empagliflozin (HR: 0.59; 95% CI: 0.26-1.3) and placebo arms of the trial (HR: 0.31; 95% CI: 0.13-0.74), treatment-by-ICD interaction P = 0.30. - Conclusions - In patients with heart failure with reduced ejection fraction enrolled in EMPEROR-Reduced, those with an ICD (vs non-ICD) experienced a lower risk of SCD regardless of empagliflozin treatment. | ||
| 650 | 4 | |a empagliflozin | |
| 650 | 4 | |a implantable cardioverter-defibrillator | |
| 650 | 4 | |a mortality | |
| 650 | 4 | |a sodium-glucose cotransporter 2 inhibitor | |
| 650 | 4 | |a sudden cardiac death | |
| 700 | 1 | |a Talha, Khawaja M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Goldenberg, Ilan |e VerfasserIn |4 aut | |
| 700 | 1 | |a Zareba, Wojciech |e VerfasserIn |4 aut | |
| 700 | 1 | |a Böhm, Michael |e VerfasserIn |4 aut | |
| 700 | 1 | |a Abdin, Amr |e VerfasserIn |4 aut | |
| 700 | 1 | |a Brückmann, Martina |d 1970- |e VerfasserIn |0 (DE-588)121145069 |0 (DE-627)705257290 |0 (DE-576)292557736 |4 aut | |
| 700 | 1 | |a Zeller, Cordula |e VerfasserIn |4 aut | |
| 700 | 1 | |a Zaremba-Pechmann, Liliana |e VerfasserIn |4 aut | |
| 700 | 1 | |a Pocock, Stuart |e VerfasserIn |4 aut | |
| 700 | 1 | |a Zannad, Faiez |e VerfasserIn |4 aut | |
| 700 | 1 | |a Anker, Stefan D. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Filippatos, Gerasimos |e VerfasserIn |4 aut | |
| 700 | 1 | |a Butler, Javed |e VerfasserIn |4 aut | |
| 700 | 1 | |a Ferreira, João Pedro |e VerfasserIn |4 aut | |
| 700 | 1 | |a Packer, Milton |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |a American College of Cardiology |t JACC Heart failure |d Amsterdam [u.a.] : Elsevier, 2013 |g 14(2026), 8 vom: Aug., Artikel-ID 103166, Seite 1-10 |h Online-Ressource |w (DE-627)73770232X |w (DE-600)2705621-1 |w (DE-576)379733455 |x 2213-1787 |7 nnas |
| 773 | 1 | 8 | |g volume:14 |g year:2026 |g number:8 |g month:08 |g elocationid:103166 |g pages:1-10 |g extent:10 |a Implantable cardioverter-defibrillator therapy in contemporary heart failure patients an analysis from the EMPEROR-reduced trial |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.jchf.2026.103166 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |7 0 |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S2213177926002660 |x Verlag |z kostenfrei |3 Volltext |7 0 |
| 951 | |a AR | ||
| 992 | |a 20260820 | ||
| 993 | |a Article | ||
| 994 | |a 2026 | ||
| 998 | |g 121145069 |a Brückmann, Martina |m 121145069:Brückmann, Martina |d 60000 |d 61000 |e 60000PB121145069 |e 61000PB121145069 |k 0/60000/ |k 1/60000/61000/ |p 7 | ||
| 999 | |a KXP-PPN1982176334 |e 5020077909 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"language":["eng"],"person":[{"display":"Aktaş, Mehmet K.","family":"Aktaş","role":"aut","given":"Mehmet K."},{"given":"Khawaja M.","role":"aut","family":"Talha","display":"Talha, Khawaja M."},{"given":"Ilan","display":"Goldenberg, Ilan","family":"Goldenberg","role":"aut"},{"given":"Wojciech","family":"Zareba","role":"aut","display":"Zareba, Wojciech"},{"display":"Böhm, Michael","role":"aut","family":"Böhm","given":"Michael"},{"family":"Abdin","role":"aut","display":"Abdin, Amr","given":"Amr"},{"given":"Martina","display":"Brückmann, Martina","family":"Brückmann","role":"aut"},{"given":"Cordula","display":"Zeller, Cordula","role":"aut","family":"Zeller"},{"display":"Zaremba-Pechmann, Liliana","family":"Zaremba-Pechmann","role":"aut","given":"Liliana"},{"given":"Stuart","display":"Pocock, Stuart","family":"Pocock","role":"aut"},{"given":"Faiez","display":"Zannad, Faiez","role":"aut","family":"Zannad"},{"given":"Stefan D.","family":"Anker","role":"aut","display":"Anker, Stefan D."},{"display":"Filippatos, Gerasimos","family":"Filippatos","role":"aut","given":"Gerasimos"},{"given":"Javed","display":"Butler, Javed","family":"Butler","role":"aut"},{"given":"João Pedro","role":"aut","family":"Ferreira","display":"Ferreira, João Pedro"},{"display":"Packer, Milton","role":"aut","family":"Packer","given":"Milton"}],"name":{"displayForm":["Mehmet K. Aktas¸, MD, MBA, Khawaja M. Talha, MD, Ilan Goldenberg, MD, Wojciech Zareba, MD, PHD, Michael Böhm, MD, Amr Abdin, MD, Martina Brueckmann, MD, Cordula Zeller, DIPL-MATH, Liliana Zaremba-Pechmann, PHD, Stuart Pocock, PHD, Faiez Zannad, MD, PHD, Stefan D. Anker, MD, PHD, Gerasimos Filippatos, MD, Javed Butler, MD, MPH, MBA, João Pedro Ferreira, MD, PHD, Milton Packer, MD"]},"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"id":{"issn":["2213-1787"],"zdb":["2705621-1"],"eki":["73770232X"]},"recId":"73770232X","origin":[{"publisher":"Elsevier ; American College of Cardiology Foundation","publisherPlace":"Amsterdam [u.a.] ; New York, NY","dateIssuedDisp":"2013-","dateIssuedKey":"2013"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"disp":"American College of CardiologyJACC Heart failure","part":{"issue":"8","extent":"10","text":"14(2026), 8 vom: Aug., Artikel-ID 103166, Seite 1-10","volume":"14","year":"2026","pages":"1-10"},"corporate":[{"role":"aut","display":"American College of Cardiology"}],"note":["Gesehen am 10.09.2025"],"title":[{"title":"JACC Heart failure","subtitle":"a journal of the American College of Cardiology","title_sort":"JACC Heart failure"}],"language":["eng"],"pubHistory":["1.2013 -"]}],"physDesc":[{"noteIll":"Diagramme","extent":"10 S."}],"note":["Online verfügbar: 2. Juli 2026, Artikelversion: 3. August 2026","Gesehen am 20.08.2026"],"id":{"eki":["1982176334"],"doi":["10.1016/j.jchf.2026.103166"]},"title":[{"title":"Implantable cardioverter-defibrillator therapy in contemporary heart failure patients","title_sort":"Implantable cardioverter-defibrillator therapy in contemporary heart failure patients","subtitle":"an analysis from the EMPEROR-reduced trial"}],"recId":"1982176334","origin":[{"dateIssuedKey":"2026","dateIssuedDisp":"August 2026"}],"type":{"bibl":"article-journal","media":"Online-Ressource"}} | ||
| SRT | |a AKTASMEHMEIMPLANTABL2026 | ||